- Home
- JLS vs ANIX Comparison
JLS vs ANIX Comparison
Compare JLS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- ANIX
- Stock Information
- Founded
- JLS 2009
- ANIX 1982
- Country
- JLS United States
- ANIX United States
- Employees
- JLS N/A
- ANIX N/A
- Industry
- JLS Investment Managers
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- ANIX Health Care
- Exchange
- JLS Nasdaq
- ANIX Nasdaq
- Market Cap
- JLS 97.1M
- ANIX 108.9M
- IPO Year
- JLS N/A
- ANIX 1987
- Fundamental
- Price
- JLS $18.93
- ANIX $3.23
- Analyst Decision
- JLS
- ANIX Strong Buy
- Analyst Count
- JLS 0
- ANIX 3
- Target Price
- JLS N/A
- ANIX $9.00
- AVG Volume (30 Days)
- JLS 26.6K
- ANIX 242.9K
- Earning Date
- JLS 01-01-0001
- ANIX 05-28-2025
- Dividend Yield
- JLS 9.33%
- ANIX N/A
- EPS Growth
- JLS N/A
- ANIX N/A
- EPS
- JLS N/A
- ANIX N/A
- Revenue
- JLS N/A
- ANIX N/A
- Revenue This Year
- JLS N/A
- ANIX N/A
- Revenue Next Year
- JLS N/A
- ANIX N/A
- P/E Ratio
- JLS N/A
- ANIX N/A
- Revenue Growth
- JLS N/A
- ANIX N/A
- 52 Week Low
- JLS $15.48
- ANIX $2.07
- 52 Week High
- JLS $17.97
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- JLS 73.80
- ANIX 51.53
- Support Level
- JLS $18.39
- ANIX $3.18
- Resistance Level
- JLS $18.89
- ANIX $3.33
- Average True Range (ATR)
- JLS 0.17
- ANIX 0.22
- MACD
- JLS 0.04
- ANIX -0.05
- Stochastic Oscillator
- JLS 98.65
- ANIX 12.31
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.